Rosen law firm, reminds abeona therapeutics inc. investors of important deadline in securities-class action-abeo

Rosen law firm reminds purchasers of the securities of abeona therapeutics inc. between may 31, 2018 and september 23, 2019, inclusive of the important january 2, 2020 lead plaintiff deadline in the securities class action. the lawsuit seeks to recover damages for abeona investors under the federal securities laws. according to the lawsuit, defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (1) abeona's chemical, manufacturing and controls ("cmc") and internal controls and procedures and/or compliance policies were inadequate; (2) abeona failed to provide sufficient data points on the transport stability of eb-101 to clinical sites, or such transport stability was insufficient; (3) it was foreseeable that the u.s. food and drug administration ("fda") would reject approval for the start of the vital study until such issues were addressed; and (4) as a result, abeona's public statements were materially false and misleading at all relevant times. when the true details entered the market, the lawsuit claims that investors suffered damages.
ABEO Ratings Summary
ABEO Quant Ranking